Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Agios Pharma (AGIO – Research Report) yesterday and set a price target of $57.00. Alec Stranahan has given his Buy ...

Under the terms of the agreement, Royalty Pharma will pay Agios $905 million in upfront cash on FDA approval of vorasidenib in exchange for a 15% royalty on annual U.S. net sales of vorasidenib up ...

Agios Pharmaceuticals has one product on the market, PYRUKYND, which has seen limited sales to date. Read more on how the product is being evaluated to treat much larger indications.

On May 4, Agios Pharmaceuticals will report latest earnings.Analysts predict losses per share of $1.701.Go here to watch Agios Pharmaceuticals sto ...

The Agios Pharmaceuticals logo is seen on a smartphone and a PC screen. (Pavlo Gonchar/Zuma Press) Stocks for two biotechnology companies jumped Wednesday after the companies reported promising ...